By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics said today that Italian biotech and molecular diagnostics company Biodiversity will develop and commercialize tests tailored for BD's platform for the detection of infections in transplant patients, as part of a regional collaboration.

Biodiversity will develop a portfolio of molecular assays to run on the BD Max System's open architecture. The assays will be for patients who have undergone transplants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.